Imugene Ltd
Research Imugene Ltd (IMU) on Bullrun: market cap AUD 40.16M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMU
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 40.16M
- Financial periodFY2025
- Net income-AUD 69.02M
- Free cash flow-AUD 90.03M
Valuation Snapshot
latest market cap is AUD 40.16M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 69.02M | -AUD 90.03M | n/a | -0.32 | AUD 21.94M | AUD 10.65M | AUD 45.03M |
| FY2024 | n/a | -AUD 149.68M | -AUD 114.82M | n/a | -0.72 | AUD 93.11M | AUD 1.55M | AUD 118.25M |
| FY2023 | n/a | -AUD 39.17M | -AUD 31.66M | n/a | -0.21 | AUD 153.15M | AUD 553.47K | AUD 193.02M |
| FY2022 | n/a | -AUD 37.87M | -AUD 31.13M | n/a | -0.23 | AUD 99.89M | AUD 673.43K | AUD 138.70M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 40.16M | n/a | n/a | n/a |
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Imugene Ltd's market cap?
Imugene Ltd's market capitalization is AUD 40.16M.
What does Imugene Ltd do?
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.